Kaposi's sarcoma and the acquired immunodeficiency syndrome: Treatment with high and low doses of recombinant leukocyte A interferon Journal Article
| Authors: | Real, F. X.; Oettgen, H. F.; Krown, S. E. |
| Article Title: | Kaposi's sarcoma and the acquired immunodeficiency syndrome: Treatment with high and low doses of recombinant leukocyte A interferon |
| Abstract: | The efficacy of recombinant leukocyte A interferon (rIFN-αA [Roferon-A, Hoffman-La Roche, Nutley, NJ]) treatment of Kaposi's sarcoma in patients with acquired immunodeficiency syndrome was evaluated in sequential trials using high doses (36 x 106 units) and low doses (3 x 106 units) of interferon. A major response was seen in 38% of patients treated at the high dose, with a median response duration of 18 months. At the low dose, the major response rate was 3%; dose escalation to 36 x 106 units resulted in an additional major response rate of 17% in low-dose nonresponders, with a median response duration of 10 months. Four of 11 patients who achieved a complete response remain free of disease, whereas all partial responders have shown disease progression. Unacceptable toxicity occurred in 27% of patients initially treated at the high dose and only in 10% of those who had progressive dose escalation up to 36 x 106 units. Prior opportunistic infections correlated negatively with therapeutic response, whereas large tumor burden and gastrointestinal involvement did not. Responding patients showed a significantly longer survival and a lower incidence of subsequent opportunistic infections than nonresponders. However, from our study we cannot determine whether rIFN-αA has an effect on the natural history of Kaposi's sarcoma in patients with the acquired immunodeficiency syndrome. |
| Keywords: | survival; major clinical study; fatigue; drug efficacy; skin toxicity; neurotoxicity; anorexia; interleukin 2; cancer immunotherapy; liver toxicity; gastrointestinal symptom; leukopenia; thrombocytopenia; myalgia; cyclophosphamide; arthralgia; aspartate aminotransferase blood level; chill; fever; confusion; gastrointestinal toxicity; hypotension; psychological aspect; depression; cardiovascular system; xerostomia; alkaline phosphatase blood level; acquired immune deficiency syndrome; headache; drug dose; kaposi sarcoma; drug therapy; dry skin; lethargy; influenza; euphoria; adverse drug reaction; mouth; therapy; opportunistic infection; nervous system; intramuscular drug administration; vertigo; recombinant alpha2a interferon; thymopoietin; intoxication; joint; digestive system; fiacitabine; human; priority journal; forgetfulness; recombinant alpha interferon a; blood and hemopoietic system |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 4 |
| Issue: | 4 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 1986-04-01 |
| Start Page: | 544 |
| End Page: | 551 |
| Language: | English |
| DOI: | 10.1200/jco.1986.4.4.544 |
| PUBMED: | 3958767 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 18 August 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work